Accell 100
Accell Connexus
DynaGraft II

MBCP
Cancellous Bone

Osteodisc for orthopedics

 

   
 
 

Accell 100

Incorporates

  • Accell Technology
  • Isotis OrthoBiologics Processed DBM
  • 0% Inert Carrier

Benefits

  • Validated Osteoinductive Potential
  • Moldable and easy to pack into defects
  • Ready to use
 
 
 

Lot Division

Each donor lot of DBM is divided in two. Half is reserved for the final formulation.

Solubilization

The remaining half undergoes the Accell process which results in flowable carrier with osteoinductive potential.

Final Formulation

The flowable carrier is then combined with the DBM particles consisting of two components with osteoinductive potential.

E-Beam Sterilization

IsoTis OrthoBiologics terminally sterilizes every lot of Accell product with a low-dose electron beam, a process that has been demonstrated to preserve the osteoinductive potential of bone growth factors.

 
 
 
  • Skeletally mature sheep model.
  • Cylindrical 5 mm metatarsal defect created in tibial diaphysis.
  • Results after 4 weeks.
 
Control - Empty
Minimal bone regeneration observed at 4 weeks. Healing limited to area adjacent to host bone.
1st Generation DBM
Bone regeneration occurs throughout the defect, caused by the presence of osteoinductive DBM particles. The inert carrier has been metabolized.
(DynaGraft II®)
Accell
Significantly more bone formation is evident immediately adjacent to the bone repair surfaces and within the interior of the defect. We believe this occurs because of the immediate access to the BMPs in the Accell products.
(Accell 100™)
 
 

Accell Brochure
Patient Brochure
In Vivo Osteoinductivity...

   
 
 
Home / Contact us / Dental / OCF / Neurosurgery / Orthopedics / Calendar / CCR / Legal notice
© 2008 Citagenix Inc. All rights reserved